The 82nd China Pharmaceutical fair and innovation drug development strategy seminar ended successfully

On December 4, 2019, the 82nd Pharmaceutical Trade Fair kicked off in Chongqing International Expo Center 100000 drug dealers and more than 2000 enterprises gathered in Shancheng and went to the national drug Fair for a feast of "transforming and reconstructing the future" This conference will hold more than 50 high-quality Theme Conference forums, 250 expert reports and more than 30 on-site activities in the same period to jointly promote the vigorous development of China's pharmaceutical industry As an important part of the 82nd pharmaceutical fair, the seminar on innovative drug development strategy was jointly held by Beijing xinkaiyuan Pharmaceutical Technology Co., Ltd., Chongqing Yaoyou Pharmaceutical Co., Ltd and yaozhi.com The seminar will analyze the difficulties of innovative drugs at home and abroad, see through the new trend of new drug research and development in China, strive to strengthen Chinese pharmaceutical enterprises, jointly promote Chinese innovative drug enterprises to connect with the world and participate in international competition At the meeting, Liu Qiang, chairman of Chongqing Yaoyou Pharmaceutical Co., Ltd., expressed the beautiful vision of the pharmaceutical industry in his speech With the joint efforts of Chinese pharmaceutical people, the future of Chinese pharmaceutical industry will be brilliant Liu Qiang, chairman of Chongqing Yaoyou Pharmaceutical Co., Ltd., has a lot of highlights on the spot With the rapid development of science and technology, new theories, methods and technologies related to big data are more and more used in the field of medicine From preclinical to market approval, from drugs to medical devices, from research and development to marketing, big data of medicine is gradually becoming the core of supporting the development of the whole industry chain It can be said that to have data is to have value The host interprets the pharmaceutical intelligence data app for the guests on site As a professional data query app under the pharmaceutical intelligence network, the host can lift the restrictions on the location and equipment of the PC end, check the pharmaceutical data, and know the pharmaceutical news He is a personal assistant in the pocket of the pharmaceutical people On the spot of the conference, the host expressed that scanning the code or searching the drug intelligence data in the application market, submitting the registered telephone number can open the VIP privilege, and the drug intelligence data APPVIP members can send it free of charge to detonate the whole conference in 7 days, which is full of excitement Huang Wenfeng, academic director of yaozhi.com, gave a lecture Li Mei, director of chemical and biological products department and head of chemical medicine group of the original drug evaluation center, pointed out that the research and development of innovative drugs is an exploratory research process, starting from the unknown and based on the unmet clinical needs, to develop the research work of drug screening and discovery With the development of pharmaceutical research, the pharmaceutical research of innovative drugs has different research purposes in different research stages The technical requirements of pharmaceutical evaluation should adapt to the research and development stage, which can be achieved by strengthening communication and communication, and strengthening the construction of technical guidelines and standards system for evaluation At the meeting of Li Mei, director of chemical and biological products office and head of chemical and pharmaceutical team of the former drug evaluation center, Li Tianquan, co-founder and vice president of drug intelligence network, said that we prefer to use data to talk when we exchange views Although the data itself can't talk, it is a powerful tool to give all the best proofs Relying on the continuous accumulation of knowledge and information, it is very important to provide data support for the establishment of a sound quality control system when the product is launched Only by mastering enough data support can we grasp the trend of the times more effectively Mr Li Tianquan, co-founder of yaozhi.com and vice president of yaozhi.com, Ge Zhimin, vice president of Yangpu Morningstar Pharmaceutical Co., Ltd., talks about the way for cro to survive in the new era In the past 10 years, China's cro industry has completed the transition from the Enlightenment period to the rapid development, the overall business chain is becoming more and more complete, and the overall market development environment is becoming more and more perfect But under the influence of economic globalization, Chinese cro enterprises are facing more development opportunities and more challenges Ge Zhimin, vice president of Yangpu Morningstar Pharmaceutical Co., Ltd and Lei Huangshu, assistant president of Chongqing Yaoyou Pharmaceutical Co., Ltd., said that natural products have been transformed into leading compounds of cancer drugs in the past few decades, rather than being an effective anti-cancer drug itself, which has made a great contribution to medical treatment and is still an indispensable source of anti-cancer drug discovery Generally, natural products may be used as natural lead compounds to anticancer drugs or candidate drugs, not only to solve the drug efficacy, but also to improve the chemical accessibility of natural drugs and promote clinical application Liang Maozhi, assistant to the president of Chongqing Yaoyou Pharmaceutical Co., Ltd and vice director of national drug clinical trial organization and director of phase I clinical trial and Research Office of West China Hospital, said that the pharmaceutical research of new drugs has been deepened with the development of drug research, and has different research purposes in different research stages We should follow the law of drug research and development for the pharmaceutical research data of new drug application phase I clinical research, and we should also control many key points in clinical design in advance Liang Maozhi, deputy director of national drug clinical trial organization and director of phase I clinical trial research office of West China Hospital Meng Bayi, a scholar in the United States, said that at present, China is carrying out the reform of drug management laws and regulations, and has introduced a new drug management law The evaluation of drug consistency has been carried out in an all-round way At the same time, the new edition of Pharmacopoeia has been opened Our own "orange peel book" and "patent connection" systems are also under planning But we can not avoid that most of our reform contents are drawing lessons from the laws and regulations of drug management in the United States, even from their ideas, forms and methods Drug regulation has its own set of strict standards, which cannot be changed The only thing that needs to be changed is the continuous improvement of our monitoring level Meng Bayi, a scholar in the United States, has become an important strategic plan for the development of modern pharmaceutical enterprises We should combine the background of the times and summarize historical experience to make better plans for future innovation and development With 35 years of experience in the operation and management of real enterprises, Westar China President coach Du Chen has made great achievements in strategic transformation, leadership improvement, human resource development and other aspects of pharmaceutical enterprises This conference brought us a keynote speech on the development strategy of innovative drugs In recent years, the research and development of new drugs by Mr duchen, President coach of MasterCard China, has been a key topic, and the discussion has never cooled down Zhou Zhongxiang, chairman of Xiamen MEDICOM Biotechnology Co., Ltd., talked about how to use big data to help new drug research and development Calculation is a way The calculation of big data can help us avoid the wrong path, save a lot of manpower, capital and time cost, sharpen the knife without mistaking the firewood cutter, master the calculation, and master a shortcut of new drug research and development Zhou Zhongxiang, chairman of Xiamen meidikang Biotechnology Co., Ltd Mr Ge Zhimin served as the chair Li Mei, former director of chemical and biological products office and head of chemical and pharmaceutical group of drug evaluation center, Zhou Zhongxiang, chairman of Xiamen MEDICOM Biotechnology Co., Ltd., Lei Huangshu, President Assistant of Chongqing Yaoyou Pharmaceutical Co., Ltd., Chen Xiaoyong, chairman of Chongqing Dongde pharmaceutical Technology Co., Ltd., Wang Dongmei, deputy general manager of Huashi Kangyuan, focused on "new drug innovation" The theme of "mode discussion" is widely and deeply studied The biggest significance of the MAH system of the round table is to make the elements of the pharmaceutical market flow flexibly and to entrust other production enterprises or sales and operation enterprises to sell Chen Xiaoyong, chairman of Chongqing Dongde Pharmaceutical Technology Co., Ltd., pointed out that under this system, the R & D enterprises should rethink their own development path Yang Chunxu, President of Chongqing Dongde Pharmaceutical Technology Co., Ltd Chen Xiaoyong, consultant of R & D risk management of Huashi Kangyuan International Pharmaceutical Co., Ltd., said that as a pharmaceutical person, in looking back on the development process of China's drug vigilance industry, it mainly includes quantity period, quality period and academic period In 2018, marked by the promulgation of announcement 66 requiring the establishment of direct reporting system for drug listing license holders, China's drug vigilance industry opened a new chapter and entered the academic period Entering the academic period, under the whole international environment, grasp the international opportunities and challenges, and further improve the management ability, risk management and control ability, and compensation ability in drug approval, so as to realize overtaking in a corner Yang Chunxu, risk management consultant of Kangyuan international pharmaceutical research and development of Huashi pharmacy, was in the sea of knowledge, in the warm voice of discussion, when experts expressed their opinions, and in the reluctance of colleagues at the meeting, the meeting ended We look forward to the coming of the next drug fair forum with great enthusiasm! Editor in charge | don't know the statement: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.